Wednesday, July 2, 2025

Psyched Wellness Increases Bought Deal To $5.5 Million

Psyched Wellness (CSE: PSYC) has increased the size of its bought deal private placement as a result of strong demand from shareholders. Previously pegged at $3.0 million, the financing has now nearly doubled to that of $5.5 million.

The financing, lead by Canaccord Genuity, will see units of the company sold at a price of $0.31 per unit. Each unit contains one common share and one common share purchase warrant, with each warrant having an exercise price of $0.43 per common share and an expiry of three years from the date of issue.

Warrants issued under the financing are also subject to an acceleration clause, enabling the company to accelerate the expiry of the warrant if the equity trades above $0.70 for a period of five trading days on a volume weighted basis. An over-allotment option has also been granted to the underwriters.

Net proceeds from the financing are to be used to fully fund pre-clinical trials of the firms amanita muscaria mushroom extract, and to further scientific research on the formulation. Proceeds are also to be spent on general corporate purposes.

Psyched Wellness last traded at $0.37 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

Psyched Wellness Sees Positive Initial Results From AME-1 Extract Study

Psyched Wellness (CSE: PSYC) this morning provided an update on its study to determine the...

Thursday, February 4, 2021, 07:33:40 AM

Psyched Wellness Attracts Major Investment

Jeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode...

Friday, June 9, 2023, 01:30:00 PM

Psyched Wellness Announces Study On Muscimol Antioxidant and Anti-Inflammatory Properties

Psyched Wellness (CSE: PSYC) has begun yet another study related to that of the Amanita...

Wednesday, January 6, 2021, 07:48:08 AM

Psyched Wellness To Conduct Stability Tests On Proprietary Mushroom Extract

Psyched Wellness (CSE: PSYC) is progressing with the development of its flagship product, an extract...

Monday, July 26, 2021, 09:28:00 AM

Psyched Wellness Adds Amanita Muscaria Expert To Advisory Board

Kevin Feeney has joined the advisory board of that of Psyched Wellness (CSE: PSYC) as...

Thursday, November 26, 2020, 07:16:39 AM